- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Victory Square Technologies Inc. Acquires 25% of Insight Diagnostics
Victory Square Technologies (CSE:VST) has announced that pursuant to an investment agreement executed between Victory Square Health, a wholly-owned subsidiary of the company, and Insight Diagnostics, Victory Square Health has acquired 25 percent of the issued and outstanding shares of Insight for a $100,000 and 5 percent of the common shares of Victory Square Heaelth. …
Victory Square Technologies (CSE:VST) has announced that pursuant to an investment agreement executed between Victory Square Health, a wholly-owned subsidiary of the company, and Insight Diagnostics, Victory Square Health has acquired 25 percent of the issued and outstanding shares of Insight for a $100,000 and 5 percent of the common shares of Victory Square Heaelth.
As quoted in the press release:
“We appreciate the position that Insight Diagnostics has gained on the strength of its work in personalized health and Type II diabetes, in particular,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “We are excited by the opportunity to partner with them as leaders in this space. This is an acquisition that is fully aligned with our newly created subsidiary, and we can now continue to build on the foundational work to date by the team at Insight.”
Insight is developing a personalized diagnostic solution for the improved management and prevention of Type II diabetes and will operate as a frontline affiliate of Victory Square’s new health-focused subsidiary, Victory Square Health. Insight CEO Dean Sutton will retain his operating responsibilities and will assume a senior role within Victory Square Health.
“Our team at Insight is delighted to be partnering with Victory Square Technologies and its Victory Square Health subsidiary,” said Dean Sutton. “We’re certainly inspired by the big picture vision and we’re energized by the opportunity to not only continue to develop Insight, but to contribute to Victory Square’s vision for making a difference in personalized health.”
Insight Diagnostics originally developed core technology at the University of Waterloo and it was further developed at Simon Fraser University in the Venture Connection Program. A PhD student and computer engineering team partnered with Dean Sutton to develop the technology into a business, which benefitted from two of Canada’s top startup accelerators, Wavefront Accelerator and Creative Destruction lab, where stringent curriculums and market validating processes were instrumental to the development of Insights commercially viable plan.
“With the close of this transaction, Victory Square Health will have the ability to leverage the data and partnerships that Insight and their leadership bring to the table,” added Tejani.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.